Göbel, Andy
Rachner, Tilman D.
Hoffmann, Oliver
Klotz, Daniel Martin
Kasimir-Bauer, Sabine
Kimmig, Rainer
Hofbauer, Lorenz C.
Bittner, Ann-Kathrin
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (GO 3055/4-1, HO 1875/27-1, RA 2151/5-1, RA 2151/7-1)
Deutsche Krebshilfe
Technische Universität Dresden
Article History
Received: 29 September 2023
Accepted: 14 February 2024
First Online: 28 February 2024
Declarations
:
: SKB is a consultant for QIAGEN, Hilden, Germany. The authors have received honoraria, unrestricted educational grants and research funding from to the individual or the institution by Alexion (LCH), Amgen (AKB, LCH, OH), Ascendis (LCH), Astra Zeneca (AKB, OH), Daiichi Sankyo (AKB, OH), Eisai (OH), Gilead (AKB, OH), Hexal (AKB, OH), MSD (OH), Novartis (AKB, OH), Pharmacosmos (LCH), Pfizer (AKB, OH), Riemser (OH), Roche (OH), Seagen (OH), and UCB (LCH). All other authors declare no potential conflicts of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Samples of patients were obtained before therapy after written informed consent from all subjects using protocols approved by the clinical ethic committee of the University Hospital.Essen (05/2856).